The Rx Recap: June 1-7

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

Dr Mittendorf Charts Vision as ASCO President-Elect to Advance Multidisciplinary Care and Research Equity

Elizabeth Mittendorf, MD, PhD, MHCM, incoming 2026–2027 President of ASCO, aims to prioritize multidisciplinary care, workforce well-being, access to clinical trials, and the thoughtful integration of artificial intelligence in oncology. In an interview with OncLive, she emphasized strengthening mentorship and sponsorship, supporting early-career professionals, and expanding ASCO’s global impact. As a surgical oncologist, Mittendorf brings a unique perspective to team-based cancer care and is committed to advocating for sustained research funding and equitable access to evidence-based treatment. Her leadership will focus on advancing ASCO’s mission to conquer cancer while empowering the oncology workforce.

FDA approves pediatric indication for SONU wearable device to treat nasal congestion

Contemporary Pediatrics informed readers that the FDA expanded its approval of the SONU Band, an AI-enabled, drug-free device, for at-home treatment of moderate-to-severe nasal congestion in individuals aged 12 and older with allergic or non-allergic rhinitis. As the first De Novo-authorized device of its kind, SONU uses personalized acoustic vibrations—calculated via smartphone facial scans—to relieve sinus swelling and congestion in under 15 minutes. Clinical data show the band improved CPAP adherence and reduced nasal symptoms in adults with obstructive sleep apnea. Experts say this non-invasive solution offers a safe, effective alternative to medication-based treatments, especially for families seeking steroid-free options.

Chronic Hand Eczema Has Significant Impacts on Patients' Lives, Survey Reveals

A recent survey by Ipsos, sponsored by LEO Pharma and reported by The American Journal of Managed Care (AJMC), reveals the deep personal and professional impact of moderate to severe chronic hand eczema, a form of atopic dermatitis, on patients’ lives. Dermatology providers overwhelmingly reported that the condition affects patients' emotional health (93%), daily functioning (92%), sleep (85%), and self-confidence (92%). The hand-specific manifestation of eczema often causes pain, itching, cracking, and swelling, interfering with activities like typing and intimacy, while also contributing to social withdrawal and workplace challenges—86% of providers said their patients struggle at work, and 51% noted career stagnation. Despite these burdens, there are no FDA-approved topical therapies for chronic hand eczema, though delgocitinib cream showed long-term safety and efficacy in the DELTA 3 trial, potentially offering a future treatment option.

To read more about research and expert insights into hand eczema, explore our interactive digital supplement featuring an exclusive deep-dive into the state and future of chronic hand eczema care.

Addressing Underdiagnosed Diabetes Prevents Complications, Increased Mortality Rates

Research presented by Drug Topics highlights the vital role pharmacists play in identifying undiagnosed diabetes, which affects 8.7 million Americans—nearly 23% of all cases—with uninsured and marginalized populations disproportionately impacted. Undiagnosed diabetes is linked to increased mortality, chronic complications, and billions in preventable health care costs. As accessible health care providers, pharmacists are well positioned to screen at-risk individuals, provide education on lifestyle and medication adherence, and refer patients for diagnosis and treatment. The report emphasizes that integrating pharmacists into value-based care models and addressing reimbursement challenges could strengthen early intervention efforts and reduce the burden of this chronic disease.

Cannabis Found in Candy Products, Haribo Initiates Recall

Research reported by Cannabis Science and Technology detailed a voluntary recall by German confectionery company Haribo, announced May 29, 2025, after cannabis was detected in certain batches of its Happy Cola F!ZZ gummy candies. The recall, currently limited to the Netherlands, was prompted by consumer complaints of dizziness and feeling unwell after consuming the 1 kg packs. Dutch authorities (NVWA) confirmed cannabis in three tested packs and are investigating the contamination source alongside Haribo. While the total number of affected individuals and products remains unknown, Haribo emphasized consumer safety as its top priority. As a precaution, Belgium has also issued a voluntary recall despite no reported incidents.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.